Michael J. Fisher

faculty photo
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Attending Physician, Center for Childhood Cancer Research and Division of Oncology, Children's Hospital of Philadelphia
Member, Cancer Center, University of Pennsylvania
Director, Neurofibromatosis Program, Children’s Hospital of Philadelphia
Chief, Neuro-Oncology Section, Division of Oncology, Children’s Hospital of Philadelphia
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology, Children’s Hospital of Philadelphia
Department: Pediatrics

Contact information
Center for Childhood Cancer Research and Division of Oncology
The Children’s Hospital of Philadelphia
3500 Civic Center Blvd.
HUB-3589
Philadelphia, PA 19104
Office: (215)590-2800
Education:

Eberhard-Karls Universitaet, Tubingen, Germany, 1987.
B.A. (Psychology, Summa cum Laude)
Amherst College, 1989.
M.D.
Harvard Medical School (cum Laude), 1994.
Post-Graduate Training
Intern in Pediatrics, Children's Hospital, Boston, 1994-1995.
Resident in Pediatrics, Children's Hospital, Boston, 1995-1997.
Fellowship, Hematology/Oncology, The Children's Hospital of Philadelphia, 1997-2000.
Fellowship, Neuro-Oncology, The Children's Hospital of Philadelphia, 2000-2001.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Itmat Expertise

Dr. Fisher is interested in the management of brain tumors and tumors related to neurofibromatosis type 1 and in new imaging modalities for evaluation of plexiform neurofibromas and brain tumors.

Selected Publications

Kotch C*, Wagner K*, Broad JH, Minturn JE, Phillips P, Li Y, Jacobs IN, Elden LM, Fisher MJ, Belasco JB: Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study. Cancers 15(9): 2621, 2023.

Avery RA, Go C, Fisher MJ, Liu GT, Garcia A, Richter M, McGeehan B, Quinn GE, Ying GS: Comparison of Visual Acuity Results Between ATS-HOTV and E-ETDRS Testing Methods in Children With Optic Pathway Gliomas. Transl Vis Sci Technol 11(3): 10, 2022.

Gross AM, Glassberg B, Wolters PL, Dombi E, Baldwin A, Fisher MJ, Kim AR, Bornhorst M, Weiss BD, Blakeley JO, Whitcomb P, Paul SM, Steinberg SM, Venzon DJ, Martin S, Carbonell A, Heisey K, Therrien J, Kapustina O, Dufek A, Derdak J, Smith MA, Widemann BC: Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofibroma At Risk for Developing Tumor-Related Morbidity. Neuro Oncol 24(11): 1978-1988, 2022.

Kotch C, Avery R, Getz KD, Bouffet E, de Blank P, Listernick R, Gutmann DH, Bornhorst M, Campen C, Liu GT, Aplenc R, Li Y, Fisher MJ: Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1. Neuro-Oncology 24(8): 1377-1386, 2022.

Brosius SN, Vossough A, Fisher MJ, Lang S-S, Beslow LA, George BJ, Ichord R: Characteristics of Moyamoya Syndrome in Pediatric Patients with Neurofibromatosis Type 1. Pediatr Neurol 134: 85-92, 2022.

Ullrich NJ, Prabhu SP, Packer RJ, Goldman S, Robison NJ, Allen JC, Viskochil DH, Gutmann DH, Perentesis JP, Korf BR, Fisher MJ, Kieran MW.: NF Clinical Trials Consortium. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. Pediatr Blood Cancer 68: e28833, 2021.

Graham RT, Abu-Arja MH, Stanek JR, Cappellano A, Coleman C, Chi S, Cooney T, Dhall G, Ellen JG, Finlay JL, Fisher MJ, Friedman GK, Gajjar A, Gauvain K, Hoffman LM, Hukin J, Lucas Jr JT, Mueller S, Navalkele P, Ronsley R, Tinkle C, Villeneuve S, Yeo KK, Su JM, Margol A, Gottardo NG, Allen J, Packer R, Bartels U, Abdelbaki MS.: Multi-institutional Analysis of Treatment Modalities in Basal Ganglia and Thalamic Germinoma. Pediatr Blood Cancer 68(10): e29172, 2021.

Fisher MJ*, Jones DTW*, Li Y, Guo X, Sonawane, PS, Waanders AJ, Phillips JJ, Weiss WA, Resnick AC, Gosline S, Banerjee J, Guinney J, Gnekow A, Kandels D, Foreman NK, Korshunov A, Ryzhova M, Massimi L, Gururangan S, Kieran MW, Wang Z, Fouladi M, Sato M, Øra I, Holm S, Markham SJ, Beck P, Jäger N, Wittmann A, Sommerkamp AC, Sahm F, Pfister SM, Gutmann DH.: Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1) Acta Neuropathologica 141(4): 605-617, 2021.

Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, Allen JC, Schorry E, Korf B, Robison NJ, Goldman S, Vinks AA, Emoto C, Fukuda T, Robinson CT, Cutter G, Edwards L, Dombi E, Ratner N, Packer R, Fisher MJ.: NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol 39(7): 797-806, 2021.

Fisher MJ*, Shih CS*, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR: Neurofibromatosis Clinical Trials Consortium, Blakeley JO, Clapp DW. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat. Med 27 (1): 165-173, 2021.

back to top
Last updated: 07/13/2023
The Trustees of the University of Pennsylvania